Using artificial intelligence, healthcare technology companies are developing the means to deliver specialty care to patients wherever they are. One such company is Tempus, which uses artificial intelligence to identify which drugs are more likely to work. Other companies such as Calibrater Health, Tempus, and Verge Genomics are working to improve the way doctors diagnose and treat patients. This article looks at some of the most innovative healthcare technology companies. It will help you decide which one is best for your organization.
Tempus
Tempus Healthcare Technology Company (NYSE: TEMP) is a biotechnology company focused on advancing precision medicine through artificial intelligence and data analytics. The company’s platform gathers and analyses multimodal patient data across several major diseases and organizes it for use by doctors. The company recently expanded into the infectious disease market in response to the COVID-19 pandemic. To date, the company has run over one million tests and currently has more than $1 billion in revenue.
The company’s labs focus on infectious diseases, cardiology, mental health, and diabetes, and has expanded into several other areas. It also offers a service to doctors that allows them to determine which treatments are most effective for patients with major depressive disorders. By analyzing patients’ genetic profiles, Tempus provides doctors with data on how to treat each patient. Tempus also offers genetic data to psychiatrists, helping them determine which medications will work best for each individual patient.
Tempus’ CEO Scott Gottlieb is a CNBC contributor and a member of the board of directors of several companies. He also sits on the board of several biotechnology companies, including Tempus and Aetion. Moreover, he is also co-chair of the Healthy Sail Panel for Royal Caribbean and Norwegian Cruise Line Holdings. So, if you’re looking for an expert in the field, Tempus Healthcare Technology Company is a great company to invest in.
Verge Genomics
The company uses data and algorithms to tackle complex problems in drug discovery. Many diseases are caused by hundreds of genes, and drugs that work in mice often do not work in humans. Because of this, the company has developed algorithms to map individual genes and predict which drugs will work. The company uses patient data in pre-clinical trials and day one to determine which drugs are likely to work in humans. This data enables drug developers to make better decisions about what drugs to develop.
Since the company launched in 2015, Verge has focused on neurodegenerative disorders, including ALS. It has also expanded its efforts to include Parkinson’s disease research. It has collaborated with several top-tier organizations, including the University of California, San Diego, and the Belgian life sciences research institute VIB. The company has identified and validated 22 novel targets for ALS and has narrowed down their lead candidates to twelve compounds.
Alice Zhang, a cofounder of Verge, was three months away from her PhD and MD graduation when she decided to launch the company. With her husband, Jason Chen, she set up the company with an aim to accelerate the drug discovery process. They were able to raise $36.5 million in total funding. After a series-A round, Verge plans to expand its pipeline of potential drugs. It has also received investment from leading life sciences companies.
Verge’s approach to drug discovery is “all-in-human.” Although animal models are useful for lower-hanging fruit, they have been proven ineffective for the long term. Verge scientists use a proprietary database of human brain tissue samples to identify the targets for drugs. This data can be used to stratify patient subpopulations and identify potential drugs. In addition, Verge scientists can turn patient’s skin cells into brain cells to test how well drugs work on brain cells.
Tempus uses artificial intelligence to determine which drugs have a higher likelihood of success
A new technology developed by Tempus is helping pharmaceutical companies make decisions on which drugs to develop based on data from clinical trials. The company has developed an artificial intelligence (AI) platform called Edge that allows pathologists to access AI models for identifying biomarkers that are actionable using a single H&E slide. With access to more than 50 petabytes of de-identified multimodal data, Tempus has been able to build AI models to identify patients that could benefit from additional testing and targeted therapies.
Tempus has partnered with Geisinger health system to develop an AI model for predicting undiagnosed structural heart disease (SHD). This disease affects the walls, chambers, and valves of the heart. It can be debilitating, and early detection can improve patient outcomes. Geisinger researchers developed the AI model to flag patients at risk for developing SHD.
AI is also useful in other areas of medicine. Companies like Pharos iBT, based in Korea, use AI to analyze massive databases and identify antibodies with desired properties. By leveraging genetic information and patient’s past medical history, Pharos iBT is helping to find breakthrough treatments for cancer and leukemia. AI also has applications in the areas of protein engineering, metabolic pathways, and disease prediction.
The AI-powered system can analyze and classify compound libraries for efficacy in cancer and other diseases. The software can also identify potential new drug candidates from public libraries, shorten the preclinical phase, and lower costs for drug development. The AI can analyze a wide range of data, including gene expression, to identify biologic targets. It can even predict the pharmacology of potential new drugs.
Calibrater Health
In the real-time world of health, customer service is key. Providing exceptional customer service will earn you the loyalty and trust of your patients. That’s why Calibrater Health is building a customer service platform for healthcare, which combines real-time patient feedback with a ticketing system and issue tracking system. If you haven’t heard of WELL, it’s a healthcare technology company you should check out.
Calibrate was founded by Isabelle McLaughlin, a seasoned business and operations leader who previously led the growth team and strategic partnerships & communications at Capsule, a pharmacy startup that raised $570 million. Before founding her own company, she worked at well-known consumer brands in London and New York. She has been named to Forbes’ 30 Under 30 list in the retail and e-commerce category. She graduated from the University of Pennsylvania.
Reflexion Health develops and implements prescription software with motion-tracking technology. The company’s Vera virtual exercise rehabilitation assistant monitors patient performance and provides audio-visual feedback. Verge facilitates telehealth visits between healthcare providers and patients. Founded by neuroscience and machine learning experts, the company uses artificial intelligence to identify the best drugs for patients. The company’s software allows for real-time monitoring of patient outcomes and makes it easier to manage and measure cost-effectiveness.
Doximity is the largest healthcare professional network in the US. With over 70 percent of physicians and 45% of NPs as members, Doximity is a powerful tool for connecting and interacting with other healthcare professionals. The app allows doctors and NPs to text or call patients to provide better care. Increasing access to data will save lives. With a wealth of resources available online, the benefits of telemedicine are limitless.
Bswift
Aetna has announced a deal to purchase privately held bswift, a provider of technology for employers and health insurance exchanges. Its products and services include benefits administration technology and a buying assistance program. The deal is expected to close by the end of the year, and is expected to have a neutral impact on Aetna’s operating earnings per share in 2014 and 2015.
The company’s mission is to help people make smart health care decisions through technology. The company’s interactive decision support system enables consumers to make informed decisions, which saves time and money for employers. The company’s technology also supports employee engagement and ACA compliance. Its services are offered through a cloud-based environment. Its customers include employers and small businesses alike. Among the benefits offered are health plan customization, a customizable online experience, and self-service enrollment.
Employee benefit administration is a key part of the company’s services, and bswift offers cloud-based software that makes the process simple and affordable for employers. The company’s benefits and payroll software allow employers to reduce costs while still delivering high-quality service to their clients. Employees’ ratings on Comparably show that Bswift’s culture is average, but the people working there aren’t satisfied with their work life. However, they say they are committed to the mission and vision of the company.
Click here for more article like this
Bswift has expanded its role as an independent national provider of benefits administration software and services. With its direct-to-employer customer base, the company also has a vibrant reseller channel that helps clients implement bswift technology. Its Exchange Solutions unit is partnering with various sponsors to launch new exchanges. bswift’s product suite is aimed at improving employee engagement.